Assessment of PMS2 Expression in Iraqi Patients with Endometrial Cancer

Abstract

Background: Endometrial carcinoma (EC) represented the sixth most common cancer amongst women worldwide.Postmitoticsegregation increased 2 (PMS2) is a gene that encrypts a protein that rolesin DNA mismatch repair (MMR).Objectives:To assessment the expression of the PMS2in endometrial tumors and knowing the extent of disease's progression through the interaction between the secretion on the surfaces of the pathological cells with the PMS2 marker , andFinding the relationship between age,stage and grade of tumors with expression of the PMS2 marker.Material and methods:Overall of seventy samples of paraffin embedded tissue blocks of diverse endometrium tissue cancerincluding 30 malignant with ages ranging from 30 to 70 years, 30 benign with ages from 20 to 60 years and 10 health endometrium biopsies as a control with ages ranging from 30 to 40 years. Results:The findings of this task demonstrated substantial variation in the expression of PMS2 between endometrial benign and malignant tumors (P<0.001). Furthermore, significant correlation was found between PMS2 with histological grade in malignant cases. There wasno significant variation in PMS2 expression with age and pathological stage. Conclusion:This allowed us to suggest that PMS2 hasadvantageous for managing of endometrial cancer in patients with DNAMMR.